CellforCure
- Company typePrivate
- Founded2010
- HeadquartersParis, France
- Headcount101–250
- GTM typeB2B
- OfferingServices
CellforCure firmographics
Firmographics- Name
- CellforCure
- Legal name
- CELLforCURE
- Website
- https://cellforcure.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
CellforCure industry classification
Industry- Product category
- Biopharmaceutical CDMO Services
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Cell Therapy CDMO (Autologous/Allogeneic Manufacturing) (HLAGAGAA)
- akta.pro secondary industries
- Cell Therapy CDMO (HLAGABAD), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
Keywords
Where CellforCure is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
CellforCure business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Infrastructure, Operations, Technology or R&D, Marketing or Sales
Revenue model
- CDMO Manufacturing Services: CELLforCURE generates revenue through contract development and manufacturing services for biotech companies developing cell and gene therapies. As a CDMO, the company provides GMP manufacturing capacity and expertise on a project-by-project basis, serving as a strategic manufacturing partner for therapy developers from clinical through commercial stages.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels1 record
CellforCure product offering
Product offeringCore offering
CELLforCURE is a contract development and manufacturing organization (CDMO) providing GMP-certified manufacturing of Advanced Therapy Medicinal Products (ATMPs), including cell and gene therapies. The company operates a 10,000 m² one-stop-shop facility in France with 3,000 m² of EMA-authorized, FDA-compliant GMP cleanroom space, supporting therapy developers from early-stage development through Phase III clinical trials to commercial launch.
Product overview
CELLforCURE, part of the France-based SEQENS Group, operates as a contract development and manufacturing organization (CDMO) specializing in GMP manufacturing of advanced therapy medicinal products (ATMPs). The company provides a one-stop-shop manufacturing platform offering integrated GMP manufacturing space across its EMA-authorized, FDA-compliant facility in France. CELLforCURE's core service encompasses cell therapy manufacturing and support for therapy developers in scaling from early-stage development through clinical trials to commercial launch.
Differentiator
Problem solved
Functional benefit
Products and services
- CELLforCURE GMP Manufacturing Services
Companies that use CellforCure
Customer profileNamed customers2 records
Segments1 record
Ideal customer profiles1 record
CellforCure technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
CellforCure partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- BBG Advanced Therapies (BioBridge Global)coreBBG Advanced Therapies, a subsidiary of BioBridge Global based in San Antonio, Texas, partnered with CELLforCURE to create a transatlantic manufacturing network for ATMPs. The collaboration combines BBG's 9 cGMP cleanrooms in Texas with CELLforCURE's European GMP facilities, enabling U.S. companies to access European manufacturing and vice versa. This partnership supports therapy developers scaling from early-stage development through multinational clinical trials to commercial launch.
- CellProtheracoreCellProthera partnered with CELLforCURE as its CDMO for Phase III manufacturing and commercialization of the ProtheraCytes cell therapy. CELLforCURE provides GMP manufacturing services to support the pivotal Phase 3 trial in the USA and Europe for the stem cell therapy targeting ischemic heart disease.
Scale indicators3 records
Recent moves5 records
Expansion highlights4 records
CellforCure competitors and assessment
Company assessmentDirect peers
- Yposkesi: Yposkesi is a France-based CDMO specializing in cell and gene therapy GMP manufacturing, located near Paris. It is the most direct European peer to CellforCure, competing for the same ATMP developers with overlapping regulatory credentials (EMA/FDA) and similar scale.
- GenIbet (currently Genezen): GenIbet/Genezen is a specialized viral vector and cell therapy CDMO offering GMP manufacturing for gene-modified cell therapies. It is comparable as a niche cell-therapy-focused CDMO targeting the same biotech customer base as CellforCure.
Regional players
- RoslinCT: RoslinCT is a UK-based cell therapy CDMO offering GMP manufacturing for cell and gene therapies. It is a regional peer to CellforCure with comparable scale and a similar focus on clinical and commercial ATMP manufacturing, primarily serving European clients.
Broad incumbents
- AGC Biologics: AGC Biologics is a global CDMO offering cell and gene therapy, viral vector, and biologics manufacturing services. It is comparable as a multi-modality CDMO with growing ATMP capacity competing for cell therapy manufacturing contracts, with broader modality coverage than CellforCure.
- Lonza Cell & Gene Technologies: Lonza is a global CDMO leader with a dedicated cell and gene therapy manufacturing business offering GMP manufacturing, process development, and commercial supply. It is comparable as a large incumbent competing directly with CellforCure for ATMP manufacturing contracts, but at significantly greater scale and geographic reach.
- Catalent (Paragon Gene Therapy / MaSTherCell): Catalent's cell and gene therapy services (including the MaSTherCell acquisition) provide viral vector and cell therapy CDMO capabilities to biotech developers. It is comparable as a multi-modality CDMO serving the same ATMP customer base as CellforCure, though it is a much larger, diversified organization.
- Thermo Fisher Scientific (Brammer Bio): Through the Brammer Bio acquisition, Thermo Fisher provides viral vector and gene therapy CDMO services. It is a broad incumbent serving overlapping cell and gene therapy developers with substantially larger resources than CellforCure.
Emerging players
- Center for Breakthrough Medicines: Center for Breakthrough Medicines is a US-based cell, gene, and biologics CDMO offering GMP manufacturing services. It competes for the same ATMP developers as CellforCure, particularly given CellforCure's transatlantic ambitions through the BBG partnership.
- CellGenix: CellGenix supplies GMP-grade raw materials and also offers development and manufacturing services for cell and gene therapy. It overlaps with CellforCure in serving ATMP developers, though it is more focused on raw materials and ancillary services than full-scale cell therapy manufacturing.
- BioElpida: BioElpida is a European cell therapy CDMO offering GMP manufacturing for cell-based therapies, including ATMPs. It is a regional, niche competitor to CellforCure serving a similar European biotech customer base.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
CellforCure compliance and trust
Trust signalCompliance2 records
CellforCure financial estimates
Financial estimateRevenue estimate
Valuation estimate
CellforCure leadership team
Management profileNumber of profiles
Profiles1 record
CellforCure funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CellforCure M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CellforCure
What does CellforCure do?
CELLforCURE is a contract development and manufacturing organization (CDMO) providing GMP-certified manufacturing of Advanced Therapy Medicinal Products (ATMPs), including cell and gene therapies. The company operates a 10,000 m² one-stop-shop facility in France with 3,000 m² of EMA-authorized, FDA-compliant GMP cleanroom space, supporting therapy developers from early-stage development through Phase III clinical trials to commercial launch.
Is CellforCure a public or private company?
CellforCure is a private company. It is classified as corporate owned and is currently operating.
When was CellforCure founded?
CellforCure was founded in 2010. It employs 101 to 250 people.
Where is CellforCure based?
CellforCure is headquartered in Paris, France, in the Europe region.
How does CellforCure make money?
One revenue line is on record: CDMO Manufacturing Services.
Who are CellforCure's main competitors?
Direct peers on record are Yposkesi and GenIbet (currently Genezen). RoslinCT is listed as a regional player. Broad incumbents are AGC Biologics, Lonza Cell & Gene Technologies, Catalent (Paragon Gene Therapy / MaSTherCell) and Thermo Fisher Scientific (Brammer Bio). Emerging players are Center for Breakthrough Medicines, CellGenix and BioElpida.
Does CellforCure have an API?
No public API is recorded for CellforCure.
What industry is CellforCure in?
CellforCure's product category is Biopharmaceutical CDMO Services. Its primary akta.pro industry code is HLAGAGAA, Cell Therapy CDMO (Autologous/Allogeneic Manufacturing), with a secondary code of HLAGABAD, Cell Therapy CDMO. Its NAICS code is 325414 and its SIC code is 8731.